Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mannatech wins patent suit

This article was originally published in The Tan Sheet

Executive Summary

As result of litigation to protect its patented glyconutrient products Ambrotose complex and Advanced Ambrotose formulas, the Coppell, Texas-based dietary supplements marketer announces that the U.S. District Court for the Northern District of Texas entered a final judgment and permanent injunction against Boston Mountain Laboratories, banning the firm from making or selling certain products for the duration of several of Mannatech's U.S. patents. Specifically, Boston Mountain Labs cannot sell BML Glyconutrient Formula, Glyco-8 and Glycoessentials, among others. Last year, the firm won patent and trademark claims it brought against Glycobiotics International for its infringing product Glycomannan (1"The Tan Sheet" July 21, 2008)

You may also be interested in...



Mannatech patents prevail again

The U.S. District Court for the Northern District of Texas prohibits Green Life and Xiong Lo from making, selling or distributing products infringing certain of Mannatech's patents. The Coppell, Texas, firm said Dec. 18 Green Life and Xiong Lo had purchased the Glyco 8 supplement from Boston Mountain Labs, against which Mannatech already prevailed in a separate patent case (1"The Tan Sheet" Oct. 12, 2009, In Brief)

Mannatech prevails over Glycoproducts

A federal judge rules Glycomannan by Glycoproducts International infringed on multiple patents held by Coppell, Texas-based Mannatech, according to Mannatech. The ruling by the U.S. District Court for the Northern District of Texas also entered a broad permanent injunction against Riggins, Idaho-based Glycoproducts to make, use or sell Glycomannan in the U.S., Mannatech says July 11. Mannatech sought the injunction following a trial jury ruling that Glycoproducts had only infringed one of two patents for Mannatech's Ambrotose glyconutrient supplement (1"The Tan Sheet" June 16, 2008, In Brief)...

Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971

It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.

Topics

UsernamePublicRestriction

Register

PS103417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel